Skip to main content
. 2015 Nov 16;127(7):849–857. doi: 10.1182/blood-2015-01-625582

Table 2.

Rates of VTE in relation to potential risk factors

No. of patients Events Person-years* AR Univariable Cox model Multivariable Cox model
Rate 95% CI HR 95% CI HR 95% CI
Stage
 Local disease 5 037 214 31.4 6.8 6.0-7.8 Ref Ref
 Regional disease 2 961 161 16.3 9.9 8.5-11.6 1.4 1.2-1.8 1.2 0.9-1.4
 Distant Metastases 470 21 1.2 18.2 11.9-28.0 2.5 1.6-4.0 1.5 1.0-2.4
 Unknown 4 734 215 23.8 9.0 7.9-10.3 1.3 1.1-1.6 1.2 0.9-1.4
Grade
 Well differentiated 1 681 71 11.1 6.4 5.1-8.1 Ref Ref
 Moderately differentiated 4 232 196 25.1 7.8 6.8-9.0 1.3 1.0-1.7 1.1 0.8-1.5
 Poorly differentiated 3 024 166 16.1 10.3 8.9-12.0 1.2 0.9-1.6 1.1 0.8-1.4
 Unknown 4 265 178 20.3 8.7 7.6-10.1 1.6 1.2-2.1 1.3 1.0-1.7
Surgery
 No surgery 3 093 104 11.5 9.0 7.4-10.9 Ref Ref
 Before surgery 13 1.5 8.7 5.1-15.0 0.9 0.5-1.6 0.7 0.4-1.2
 During surgery hospitalization 3 0.2 17.9 5.8-55.5 1.7 0.6-5.5 1.5 0.5-4.9
 First month after discharge 26 1.1 23.5 16.0-34.5 2.4 1.6-3.8 2.2 1.4-3.4
 Second month after discharge 24 1.0 24.3 16.3-36.2 2.4 1.5-3.8 1.4 0.9-2.2
 Third month after discharge 12 1.0 12.6 7.2-22.2 1.2 0.7-2.2 0.6 0.3-1.1
 Subsequent time 429 56.3 7.6 6.9-8.4 0.9 0.7-1.1 1.0 0.8-1.3
Chemotherapy
 No chemotherapy 10 429 422 57.1 7.4 6.7-8.1 Ref Ref
 Before chemotherapy 31 2.7 11.7 8.2-16.6 1.5 1.0-2.1 1.6 1.1-2.4
 During chemotherapy 1.3 59.6 47.7-74.5 7.7 6.0-9.8 10.8 8.2-14.4
 First month after completion 15 0.3 51.6 31.1-85.5 6.5 3.9-10.9 8.4 4.9-14.2
 Second month after completion 8 0.2 33.1 16.6-66.3 4.0 2.0-8.1 4.5 2.2-9.3
 Third month after completion 3 0.2 13.5 4.4-41.9 1.8 0.6-5.5 2.0 0.6-6.3
 Subsequent time 55 10.8 5.1 3.9-6.7 0.7 0.5-0.9 1.1 0.8-1.5
Endocrine therapy
 No endocrine therapy 2 323 87 9.8 8.9 7.2-11.0 Ref Ref
 Before endocrine therapy 54 3.0 17.8 13.7-23.3 1.9 1.3-2.6 1.2 0.8-1.7
 First 3 months of endocrine therapy 69 2.5 27.7 21.9-35.0 2.9 2.1-4.0 2.4 1.7-3.4
 Subsequent time 401 57.3 7.0 6.3-7.7 0.8 0.6-1.0 0.9 0.7-1.1
Body mass index (kg/m2)
 Underweight (<18.5) 192 4 1.1 3.8 1.4-10.1 0.7 0.3-2.0 0.7 0.3-1.9
 Ideal (18.5-24.9) 3 099 93 18.3 5.1 4.2-6.2 Ref Ref
 Overweight (25.0-29.9) 2 520 148 14.7 10.1 8.6-11.8 2.0 1.5-2.6 1.8 1.4-2.4
 Obese (30.0-39.9) 1 119 73 6.4 11.4 9.1-14.3 2.2 1.6-3.0 2.1 1.6-2.9
 Morbidly obese (≥40.0) 440 38 2.3 16.5 12.0-22.7 3.2 2.2-4.7 3.0 2.1-4.4
 Missing 5 832 255 29.9 8.5 7.6-9.7 1.6 1.3-2.0 1.5 1.2-1.9
Age (years)
 <40 715 21 4.1 5.1 3.4-7.9 Ref Ref
 40-49 2 030 63 12.7 5.0 3.9-6.3 1.0 0.6-1.7 1.1 0.7-1.8
 50-59 3 262 108 20.7 5.2 4.3-6.3 1.1 0.7-1.7 1.3 0.8-2.1
 60-69 2 973 179 17.7 10.1 8.7-11.7 2.1 1.3-3.3 2.9 1.8-4.6
 70-79 2 407 158 11.9 13.3 11.4-15.5 2.7 1.7-4.2 4.2 2.6-6.7
 ≥80 1 815 82 5.5 14.9 12.0-18.4 2.9 1.8-4.7 5.0 3.0-8.2
Charlson score
 0 6 987 295 37.5 7.8 7.1-8.8 Ref Ref
 1-3 5 860 293 33.6 8.7 7.8-9.8 1.1 1.0-1.4 1.0 0.8-1.1
 ≥4 355 23 1.5 15.4 10.2-23.1 2.1 1.4-3.3 1.3 0.9-2.1

Subsequent time refers to the time and rate after the procedure until the completion of follow-up.

Ref, reference.

*

Divided by 1000.

Per 1000 person-years.

HRs adjusted for all other variables in the table. All variables were fitted by using the categorization displayed in the table (ie, age group as a 6-level nonordered categorical variable).